ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OSTX vs ZYBT // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

OS Therapies Incorporated (NYSE) VS. Zhengye Biotechnology Holding Limited (Class A) (NASDAQ) • 15-METRIC TALLY: OSTX 0 — ZYBT 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OSTX VS. ZYBT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OSTX ZYBT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 20.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -22.30% -12.70 ZYBT /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -21.07% 2.61% -23.68 ZYBT /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -34.80% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 1.90 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 4/9 -3.00 ZYBT /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.8 43.1 -9.26 ZYBT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $67.6M $67.8M -$185.2K ZYBT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OSTX REV ZYBT REV OSTX GROSS % ZYBT GROSS % OSTX FCF ZYBT FCF
FY 2025 $0 $16.6M — 20.5% -$14.2M $1.8M
FY 2024 $0 $25.5M — 49.0% -$7.3M $3.8M
FY 2023 $0 — — — -$3.0M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OSTX // BETA —
ZYBT // BETA —